Oncopeptides AB (Oncopeptides)

Oncology Corporate Profile

HQ Location

Vastra Tragardsgtan 15
Stockholm, Sweden 111 52

Company Description

Oncopeptides is working to enhance oncology therapies, by creating cytosuperiors of existing basic cytotoxic compounds. Oncopeptides lead compound, named melflufen, is a cytosuperior of the chemotherapeutic alkylator melphalan.Melflufen is currently undergoing Phase II efficacy studies in patients with relapsed and/or refractory multiple myeloma. A family of enzymes that is expressed at very high levels in cancer cells, such as multiple myeloma cells, causes melflufen and its metabolites to accumulate in the diseased cells. This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, and thereby better treatment of the disease.

Website: http://www.oncopeptides.se

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
melflufencytosuperior of the chemotherapeutic alkylator melphalanMultiple MyelomaII

View additional information on product candidates here »

Source: http://www.oncopeptides.se

Recent News Headlines

There are no news items to display